PMV PHARMACEUTICALS, INC. Interest Income (Expense), Net
PMV PHARMACEUTICALS, INC. (PMVP) reported Interest Income (Expense), Net of $788.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNet · last filed 2026-08-14
- PMV PHARMACEUTICALS, INC. interest income (expense), net for the quarter ending 2026-06-30 was $788.00K, a 53.37% decline year-over-year.
- PMV PHARMACEUTICALS, INC. interest income (expense), net for the quarter ending 2026-03-31 was $980.00K, a 49.35% decline year-over-year.
- PMV PHARMACEUTICALS, INC. interest income (expense), net for the quarter ending 2025-12-31 was $1.23M, a 46.13% decline year-over-year.
- PMV PHARMACEUTICALS, INC. interest income (expense), net for the quarter ending 2025-09-30 was $1.48M, a 43.40% decline year-over-year.
- PMV PHARMACEUTICALS, INC. interest income (expense), net for fiscal 2025 was $6.34M, a 40.53% decline from fiscal 2024.
- PMV PHARMACEUTICALS, INC. interest income (expense), net for fiscal 2024 was $10.65M, a 4.62% decline from fiscal 2023.
- PMV PHARMACEUTICALS, INC. interest income (expense), net for fiscal 2023 was $11.17M, a 208.00% increase from fiscal 2022.
- PMV PHARMACEUTICALS, INC. interest income (expense), net for fiscal 2022 was $3.63M, a 707.80% increase from fiscal 2021.
| Period end | Interest Income (Expense), Net 3 month | Interest Income (Expense), Net 6 month | Interest Income (Expense), Net 9 month | Interest Income (Expense), Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $788.00K 10-Q · filed 2026-08-14 | $1.77M 10-Q · filed 2026-08-14 | $3.00M derived: sum of 3 quarters · filed 2026-08-14 | $4.48M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $980.00K 10-Q · filed 2026-05-12 | $2.21M derived: sum of 2 quarters · filed 2026-05-12 | $3.69M derived: sum of 3 quarters · filed 2026-05-12 | $5.38M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $2.71M derived: sum of 2 quarters · filed 2026-03-06 | $4.40M derived: sum of 3 quarters · filed 2026-08-14 | $6.34M 10-K · filed 2026-03-06 |
| 2025-09-30 | $1.48M 10-Q · filed 2025-11-12 | $3.17M derived: sum of 2 quarters · filed 2026-08-14 | $5.11M 10-Q · filed 2025-11-12 | $7.39M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $1.69M 10-Q · filed 2026-08-14 | $3.63M 10-Q · filed 2026-08-14 | $5.91M derived: sum of 3 quarters · filed 2026-08-14 | $8.53M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $1.94M 10-Q · filed 2026-05-12 | $4.22M derived: sum of 2 quarters · filed 2026-05-12 | $6.84M derived: sum of 3 quarters · filed 2026-05-12 | $9.64M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $2.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $4.90M derived: sum of 2 quarters · filed 2026-03-06 | $7.70M derived: sum of 3 quarters · filed 2026-03-06 | $10.65M 10-K · filed 2026-03-06 |
| 2024-09-30 | $2.62M 10-Q · filed 2025-11-12 | $5.42M derived: sum of 2 quarters · filed 2025-11-12 | $8.37M 10-Q · filed 2025-11-12 | $11.53M derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-06-30 | $2.80M 10-Q · filed 2025-08-07 | $5.75M 10-Q · filed 2025-08-07 | $8.92M derived: sum of 3 quarters · filed 2026-03-06 | $11.90M derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-03-31 | $2.95M 10-Q · filed 2025-05-09 | $6.12M derived: sum of 2 quarters · filed 2026-03-06 | $9.10M derived: sum of 3 quarters · filed 2026-03-06 | $11.80M derived: sum of 4 quarters · filed 2026-03-06 |
| 2023-12-31 | $3.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $6.15M derived: sum of 2 quarters · filed 2026-03-06 | $8.85M derived: sum of 3 quarters · filed 2026-03-06 | $11.17M 10-K · filed 2026-03-06 |
| 2023-09-30 | $2.98M 10-Q · filed 2024-11-07 | $5.68M derived: sum of 2 quarters · filed 2024-11-07 | $8.01M 10-Q · filed 2024-11-07 | $9.80M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $2.70M 10-Q · filed 2024-08-08 | $5.02M 10-Q · filed 2024-08-08 | $6.82M derived: sum of 3 quarters · filed 2025-03-03 | $7.94M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $2.33M 10-Q · filed 2024-05-09 | $4.12M derived: sum of 2 quarters · filed 2025-03-03 | $5.25M derived: sum of 3 quarters · filed 2025-03-03 | $5.85M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $2.92M derived: sum of 2 quarters · filed 2025-03-03 | $3.52M derived: sum of 3 quarters · filed 2025-03-03 | $3.63M 10-K · filed 2025-03-03 |
| 2022-09-30 | $1.12M 10-Q · filed 2023-11-09 | $1.73M derived: sum of 2 quarters · filed 2023-11-09 | $1.83M 10-Q · filed 2023-11-09 | $2.06M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $604.00K 10-Q · filed 2023-08-09 | $832.00K 10-Q · filed 2023-08-09 | $939.00K derived: sum of 3 quarters · filed 2024-02-29 | $1.04M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $229.00K 10-Q · filed 2023-05-10 | $335.00K derived: sum of 2 quarters · filed 2024-02-29 | $437.00K derived: sum of 3 quarters · filed 2024-02-29 | $550.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $106.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $208.00K derived: sum of 2 quarters · filed 2024-02-29 | $321.00K derived: sum of 3 quarters · filed 2024-02-29 | $449.00K 10-K · filed 2024-02-29 |
| 2021-09-30 | $102.00K 10-Q · filed 2022-11-08 | $215.00K derived: sum of 2 quarters · filed 2022-11-08 | $343.00K 10-Q · filed 2022-11-08 | $391.00K derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $113.00K 10-Q · filed 2022-08-09 | $241.00K 10-Q · filed 2022-08-09 | $289.00K derived: sum of 3 quarters · filed 2023-03-01 | $329.00K derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $128.00K 10-Q · filed 2022-05-10 | $176.00K derived: sum of 2 quarters · filed 2023-03-01 | $216.00K derived: sum of 3 quarters · filed 2023-03-01 | $373.00K derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $48.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $88.00K derived: sum of 2 quarters · filed 2023-03-01 | $245.00K derived: sum of 3 quarters · filed 2023-03-01 | $651.00K 10-K · filed 2023-03-01 |
| 2020-09-30 | $40.00K 10-Q · filed 2021-11-12 | $197.00K derived: sum of 2 quarters · filed 2021-11-12 | $603.00K 10-Q · filed 2021-11-12 | $919.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $157.00K 10-Q · filed 2021-08-13 | $563.00K 10-Q · filed 2021-08-13 | $879.00K derived: sum of 3 quarters · filed 2022-03-01 | $1.15M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $406.00K 10-Q · filed 2021-05-14 | $722.00K derived: sum of 2 quarters · filed 2022-03-01 | $994.00K derived: sum of 3 quarters · filed 2022-03-01 | |
| 2019-12-31 | $316.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $588.00K derived: sum of 2 quarters · filed 2022-03-01 | $1.30M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $272.00K 10-Q · filed 2020-11-13 | $985.00K 10-Q · filed 2020-11-13 | ||
| 2018-12-31 | $1.34M 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |